MID-VOLUME · FEMALE-LED
liothyronine Side Effects
liothyronine (also sold as Cytomel) sits MID-VOLUME #340 of 524 by FAERS report count. Lead signal: FEMALE-LED - 89% of sex-coded reports are female (6,866 F / 852 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 8,408
- FAERS reports
FDA Adverse Event Reporting System extract for liothyronine. Stamp set WATCHLIST · DEATH-MARKED · HOSP-MID. How figures are compiled.
liothyronine reporting skew - 89% of sex-coded reports are female (6,866 F / 852 M). Volume band MID-VOLUME #340 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for liothyronine (Cytomel) (8,408 reports). Signature FEMALE-LED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
HEADACHE leads 859 of 8,408 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (89% of sex-coded rows)
Age peak 45-64 (2,556 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 195 reports (2.3% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 92 |
| COMPLETED SUICIDE | 23 |
| DYSPNOEA | 15 |
| FALL | 13 |
| TOXICITY TO VARIOUS AGENTS | 12 |
| NAUSEA | 10 |
| PYREXIA | 9 |
| SEPSIS | 9 |
| CARDIAC ARREST | 8 |
| ATRIAL FIBRILLATION | 7 |
| COUGH | 7 |
| DIARRHOEA | 7 |
| PAIN | 7 |
| PLEURAL EFFUSION | 7 |
| RENAL FAILURE | 7 |
| RESPIRATORY FAILURE | 7 |
| VOMITING | 7 |
| CONDITION AGGRAVATED | 6 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 6 |
Reactions in Hospitalization Reports
Hospitalization mid-share (1,457, 17.3%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| HEADACHE | 317 |
| HYPERTENSION | 281 |
| DYSPNOEA | 268 |
| HYPOTHYROIDISM | 243 |
| ASTHMA | 240 |
| CARDIAC DISORDER | 238 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 227 |
| BURNING SENSATION | 222 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 222 |
| FIBROMYALGIA | 219 |
| CARPAL TUNNEL SYNDROME | 217 |
| SLEEP APNOEA SYNDROME | 214 |
| RHINITIS ALLERGIC | 213 |
| BLOOD TEST ABNORMAL | 212 |
| SENSITISATION | 211 |
| POLYCYSTIC OVARIES | 209 |
| SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION | 200 |
| LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES | 191 |
| RENAL DISORDER | 185 |
| EJECTION FRACTION | 176 |
How to read liothyronine FAERS figures (WATCHLIST · DEATH-MARKED · HOSP-MID)
FAERS holds 8,408 voluntary reports linked to liothyronine (Cytomel), 2004-2025. Death is listed on 195 (2.3%). Hospitalization appears on 1,457 (17.3%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-MARKED · HOSP-MID as signal-detection rates next to 89% of sex-coded reports are female (6,866 F / 852 M).
Read with liothyronine
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 8,423 FAERS cases (Δ 15 heavier vs liothyronine); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 8,426 FAERS cases (Δ 18 heavier vs liothyronine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 8,461 FAERS cases (Δ 53 heavier vs liothyronine); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 8,521 FAERS cases (Δ 113 heavier vs liothyronine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 59.8 pp vs liothyronine's DEATH-MARKED): CASELOAD · HOSP-MID.
liothyronine stamps WATCHLIST · FEMALE-LED; class peers and methodology beat restating the same FAERS caveats on every effects URL.